While our experiments were focused on H3.3K27M tumor cells, both these studies show similar effects on H3.1K27M cells, suggesting that targeting the SWI/SNF complex may be a key therapeutic strategy for H3.3/H3.1K27M DIPGs and DMGs. Here, SMARCA1 is linked to neoplasm.